期刊
MOLECULAR ONCOLOGY
卷 17, 期 5, 页码 765-778出版社
WILEY
DOI: 10.1002/1878-0261.13348
关键词
ALK rearrangements; DNA-based NGS; genomic breakpoints; non-small cell lung cancer; RNA-based NGS
类别
ALK rearrangement, also known as the 'diamond mutation' in non-small cell lung cancer (NSCLC), plays a crucial role in determining the suitable candidates for ALK inhibitors. In this study, DNA-based next-generation sequencing (NGS) was used to identify ALK rearrangement-positive NSCLC cases and analyze their genomic breakpoints. The findings highlight the necessity of using RNA-based assays to confirm functional RNA fusions in cases with uncommon or frameshift rearrangements.
ALK rearrangement is called the 'diamond mutation' in non-small cell lung cancer (NSCLC). Accurately identifying patients who are candidates for ALK inhibitors is a key step in making clinical treatment decisions. In this study, a total of 783 ALK rearrangement-positive NSCLC cases were identified by DNA-based next-generation sequencing (NGS), including 731 patients with EML4-ALK and 52 patients with other ALK rearrangements. Diverse genomic breakpoints of ALK rearrangements were identified. Approximately 94.4% (739/783) of the cases carried ALK rearrangements with genomic breakpoints in the introns of ALK and its partner genes, and 2.8% (21/739) of these cases resulted in frameshift transcripts of ALK. Meanwhile, 5.6% (44/783) of the ALK rearrangement-positive cases had breakpoints in the exons that would be expected to result in abnormal transcripts. RNA-based NGS was performed to analyse the aberrant fusions at the transcript level. Some of these rearranged DNAs were not transcribed, and the others were fixed by some mechanisms so that the fusion kinase proteins could be expressed. Altogether, these findings emphasize that, when using DNA-based NGS, functional RNA fusions should be confirmed in cases with uncommon/frameshift rearrangement by RNA-based assays.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据